Literature DB >> 3252753

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

D J Hardy1, D M Hensey, J M Beyer, C Vojtko, E J McDonald, P B Fernandes.   

Abstract

The in vitro activities of several 14-, 15- and 16-membered macrolides were compared with that of erythromycin. In general, 14-membered macrolides such as erythromycin, clarithromycin, and flurithromycin were more active against streptococci and Bordetella pertussis than was the 15-membered macrolide azithromycin, which was more active than 16-membered macrolides such as miocamycin and rokitamycin. Clarithromycin was the most active compound against Streptococcus pyogenes, pneumococci, Listeria monocytogenes, and Corynebacterium species. Legionella pneumophila was most susceptible to miocamycin, clarithromycin, and rokitamycin. Branhamella catarrhalis, Neisseria gonorrhoeae, and Haemophilus influenzae were most susceptible to azithromycin. Azithromycin and dirithromycin were the most active compounds against Campylobacter jejuni. MICs of 16-membered macrolides for strains expressing inducible-type resistance to erythromycin were less than or equal to 1 microgram/ml, whereas none of the compounds had activity against strains expressing constitutive-type resistance. The MICs of roxithromycin, miocamycin, rokitamycin, and josamycin increased in the presence of human serum, whereas MICs of the other compounds either were unchanged or decreased.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252753      PMCID: PMC175956          DOI: 10.1128/AAC.32.11.1710

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro susceptibility studies with josamycin and erythromycin.

Authors:  L J Strausbaugh; J A Dilworth; J M Gwaltney; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

2.  Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.

Authors:  G A Dette; H Knothe; G Koulen
Journal:  Drugs Exp Clin Res       Date:  1987

3.  Chemical modification of erythromycins. I. Synthesis and antibacterial activity of 6-O-methylerythromycins A.

Authors:  S Morimoto; Y Takahashi; Y Watanabe; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1984-02       Impact factor: 2.649

4.  In vitro and in vivo antibacterial activity of 9,3"-Di-o-acetyl midecamycin (Mom), a new macrolide antibiotic.

Authors:  K Kawaharajo; Y Sekizawa; M Inoue
Journal:  J Antibiot (Tokyo)       Date:  1981-04       Impact factor: 2.649

5.  Acyl derivatives of 16-membered macrolides. I. Synthesis and biological properties of 3"-O-propionylleucomycin A5 (TMS-19-Q).

Authors:  H Sakakibara; O Okekawa; T Fujiwara; M Otani; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1981-08       Impact factor: 2.649

6.  A new antibiotic, josamyicn. I. Isolation and physico-chemical characteristics.

Authors:  T Osono; Y Oka; S Watanabe; Y Okami; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1967-07       Impact factor: 2.649

7.  A new antibiotic, josamycin. II. Biological studies.

Authors:  K Nitta; K Yano; F Miyamoto; Y Hasegawa; T Sato
Journal:  J Antibiot (Tokyo)       Date:  1967-07       Impact factor: 2.649

8.  In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  New fluorinated erythromycins obtained by mutasynthesis.

Authors:  L Toscano; G Fioriello; R Spagnoli; L Cappelletti; G Zanuso
Journal:  J Antibiot (Tokyo)       Date:  1983-11       Impact factor: 2.649

10.  Factors affecting the in-vitro activity of roxithromycin.

Authors:  J M Andrews; J P Ashby; R Wise
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

View more
  78 in total

1.  Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.

Authors:  R Jung; C R Messick; S L Pendland; E P Tesoro; K J Losendahl; C A Schriever; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

Authors:  D N Fish; E Abraham
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

4.  Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.

Authors:  K L Bergman; K M Olsen; T E Peddicord; P D Fey; M E Rupp
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  Absolute bioavailability of clarithromycin after oral administration in humans.

Authors:  S Y Chu; R Deaton; J Cavanaugh
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

Review 6.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 7.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

8.  Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Authors:  V Preac-Mursic; B Wilske; G Schierz; E Süss; B Gross
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-07       Impact factor: 3.267

9.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  Penetration of clarithromycin into lung tissues from patients undergoing lung resection.

Authors:  D N Fish; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.